NCT07704775 Nemolizumab Vulvar Lichen Sclerosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07704775—Nemolizumab for LS—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07704775 is a hot trial to watch

Vulvar Lichen Sclerosus is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. NCT07704775 is notable because it tests Nemolizumab in a Phase 2 design while A ≥ 4-point improvement in Itch NRS score serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Enrollment of 25 participants across United States shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: A ≥ 4-point improvement in Itch NRS score — Baseline to Week 24
• Secondary: Time to achieve a ≥4-point Itch NRS reduction — From Baseline to Week 24
• Secondary: Change in Clinical Photographs based on internal physician-rated severity scale — Baseline to Week 24
• Secondary: Change in Vulvar Quality of Life Index (VQLI) Score — Baseline to Week 24
• Secondary: Change in Pain NRS score — Baseline to Week 24

Benchmark readouts in the surrounding field

• ANIFROLUMAB TREATMENT IN PATIENTS WITH SJÖGREN’S DISEASE: EFFICACY AND SAFETY ASSESSMENT IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA PROOF-OF-MECHANISM TRIAL (ANISE-II) (Phase 2): CRESS response(12-week) = 10.0 % ; CRESS response(12-week) = 65.0 %
• IMPACT OF BODY MASS INDEX ON RESPONSE TO JAK INHIBITORS IN RHEUMATOID ARTHRITIS: AN INDIVIDUAL PATIENT DATA META-ANALYSIS (Phase 3): ACR20(class II) = 0.88 Unit
• TOFACITINIB PROVIDES EARLY PAIN RELIEF, BUT SIMILAR NSAID DISCONTINUATION AND T2T OUTCOMES TO ETANERCEPT IN RHEUMATOID ARTHRITIS: DATA FROM THE AcceleRAte RANDOMISED CLINICAL TRIAL (Phase 3): NSAID discontinuation(week 12) = 43.6 % ; NSAID discontinuation(week 12) = 41.7 %

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Nemolizumab (Approved; IL-31RA)

Company & Deal Intelligence context: The University of Texas Southwestern Medical Center — http://www.utsouthwestern.edu

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07704775 is a focused lens on Vulvar Lichen Sclerosus development. Its value will be determined by whether Nemolizumab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.